An announcement from MaxCyte ( (MXCT) ) is now available.
MaxCyte, Inc. announced the grant of stock options, restricted stock units (RSUs), and performance stock units (PSUs) to its top executives, Maher Masoud and Douglas Swirsky. These equity awards are part of the company’s strategy to align executive compensation with performance metrics and long-term shareholder value. The stock options have a 10-year exercise period with a price set at $3.29, while the RSUs and PSUs are contingent on achieving specific performance targets. This move is expected to strengthen MaxCyte’s leadership team and enhance its competitive positioning in the cell therapy market.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, providing platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics. The company has developed and commercialized its proprietary Flow Electroporation® technology over the past 20 years, which supports the expanding cell therapy market. MaxCyte’s ExPERT™ platform includes a range of instruments and processing assemblies designed to facilitate complex engineering of various cells, catering to the high-growth cell therapy sector.
YTD Price Performance: -20.99%
Average Trading Volume: 40,955
Technical Sentiment Signal: Strong Buy
Current Market Cap: £253.5M
Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.